公开(公告)号：US20210054062A1

公开(公告)日：2021-02-25

申请号：US17054469

申请日：2019-05-10

Applicant: Neuracle Science Co., Ltd. ,  Seoul National University R&DB Foundation

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN ,  Eunhwoi YOU

IPC: C07K16/24 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00 ,  A61P29/00 ,  A61P25/02

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Ina specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20200223914A1

公开(公告)日：2020-07-16

申请号：US16626625

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd. ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Bongcheol KIM ,  Eun Bee CHO ,  Dong Sik KIM ,  Jae-Keun LEE ,  Soon-gu KWON ,  Jae Young SEONG ,  Juwon SHIM ,  Tae Woo KIM ,  Shin-hyuk KANG

IPC: C07K16/24 ,  A61P35/00 ,  C07K16/30

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.